Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-05-26 AGM Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled 'Bulletin from the Annual General Meeting in Oncopeptides AB (publ)' and details the principal resolutions passed during the meeting held on May 26, 2021. Key items include the adoption of the annual report, approval of remuneration, re-election of board members, and resolutions regarding new incentive programs and share issuance authorizations. These contents are characteristic of the official minutes or summary released following an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2021-05-26 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Q1 2021' (Interim Report Q1 2021) and contains comprehensive financial statements, including a summary of group figures, income statements, and cash flow data for the period January-March 2021. It also includes detailed management commentary on business operations, clinical trials, and market performance. This fits the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q1 2021' and contains comprehensive financial statements, including a balance sheet, income statement, and cash flow data for the period of January-March 2021. It also includes a letter from the CEO, business highlights, and clinical development updates. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2021
2021-05-26 English
Phase 3 OCEAN study demonstrates that melflufen is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma
Regulatory Filings Classification · 1% confidence The document is a press release dated May 25, 2021, announcing positive topline results from the Phase 3 OCEAN study evaluating melflufen versus pomalidomide for relapsed refractory multiple myeloma. It details efficacy endpoints (PFS, ORR), safety profiles, and mentions future plans (submission to FDA in Q4 2021, presentation of complete data at a scientific congress). This content structure—announcing key clinical trial results and providing context/future plans—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical milestones. Since it focuses purely on clinical trial results and does not contain comprehensive quarterly financial statements, balance sheets, or income statements, it is best classified as an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on 'topline results' and the announcement of a webcast, ER is the most fitting category for a major clinical update press release.
2021-05-25 English
Fas 3-studien OCEAN visar att melflufen är minst lika effektivt som pomalidomid - det mest använda läkemedlet i relapserande refraktärt multipelt myelom
Regulatory Filings Classification · 1% confidence The document is a press release dated May 25, 2021, announcing positive overall results from the Phase 3 OCEAN study evaluating the drug melflufen against pomalidomide for treating relapsed/refractory multiple myeloma. It details key efficacy and safety data (PFS, ORR) and mentions plans to submit a supplemental application to the FDA in Q4 2021. This type of announcement, detailing clinical trial results and business updates, is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it focuses on the immediate release of key financial/clinical performance indicators rather than a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as clinical trial results often accompany or substitute for traditional earnings highlights in biotech. It is not a transcript (CT), a formal annual report (10-K), or a standalone audit report (AR). It is a direct announcement of results, not just an announcement that a report will follow (RPA).
2021-05-25 Swedish
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated April 30, 2021, announcing a change in the total number of outstanding shares and votes following a directed share issue completed in March and registered in April 2021. It explicitly states the increase in shares from 68,084,855 to 75,084,855. This directly relates to a change in the company's capital structure due to the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general financing update (CAP) but a specific notification of the result of a share issuance.
2021-04-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.